



Dkt. 43016-C/JPW/AKC/JKM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philip O. Livingston and Friedhelm Helling

U.S. Serial No.: 08/475,784 Group Unit: 1806

Filed: June 7, 1995 Examiner: A. Caputa

For: GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

1185 Avenue of the Americas
New York, New York 10036
May 2, 1997

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

MAY 22 1997

Sir:

GROUP 1800

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56(c) and §1.97(c), applicants would like to direct the Examiner's attention to the following disclosure which is listed on the attached Form PTO-1449 (Exhibit 1) and attached hereto as Exhibits 2-6:

1. Helling, F., et al. (March 1993) "Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma." Proceedings Of The 84th Annual Meeting Of The American 34: 491 (Exhibit 2);
2. Helling, F., et al. (August 1993) "Construction of immunogenic GD-3 conjugate vaccines." Annals Of The New York Academy Of Sciences 690: 396-397 (Exhibit 3);
3. Helling, F., et al. (1994) "GD3 vaccines for melanoma superior immunogenicity of keyhole limpet hemocyanin conjugate." Cancer Research 54: 197-203 (Exhibit 4);
4. Bystryn, J-C (1990) "Tumor vaccines." Cancer And Metastasis Reviews 9: 81-91 (Exhibit 5); and

Philip O. Livingston and Friedhelm Helling
U.S. Serial No. 08/475,784
Filed: June 7, 1995
Page 2

5. Ritter, G., et al. (1990) "Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides for Campylobacter jejuni." Int. J. Cancer 66: 184-190 (Exhibit 6).

The references, enclosed as Exhibits 2-5, were cited in the Supplementary European Search Report issued in connection with European Application No. 94 90 7279.7, filed August 22, 1995, corresponding to PCT International Application No. PCT/US94/00757, filed January 21, 1994. The subject application is a continuation application of PCT/US94/00757. A copy of the Supplementary European Search Report is attached hereto as Exhibit 7.

Further, the reference, enclosed as Exhibit 6, was cited by the New Zealand Patent Office during the substantive examination of New Zealand Application No. 261744, filed July 28, 1995, corresponding to PCT International Application No. PCT/US94/00757, filed January 21, 1994. The subject application is a continuation application of PCT/US94/00757.

Applicants maintain that the subject invention is novel and nonobvious over the teachings disclosed in the above-identified publications. Accordingly, applicants maintain that the above-identified publications neither disclose nor suggest the invention claimed in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$230.00 fee under 37 C.F.R. §1.17(p), is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any

Philip O. Livingston and Friedhelm Helling
U.S. Serial No. 08/475,784
Filed: June 7, 1995
Page 3

other fee is required, authorization is hereby given to charge
the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Albert Wai Kit Chan

I hereby certify that this correspondence
is being deposited this date with the U.S.
Postal Service with sufficient postage as
first class mail in an envelope addressed
to: Assistant Commissioner for Patents,
Washington, D.C. 20231.

Albert Wai Kit Chan 5/2/97
Albert Wai-Kit Chan Date
Reg. No. 36,479

John P. White
Registration No. 28,678
Albert Wai-Kit Chan
Registration No. 36,479
Attorneys for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Philip O. Livingston and Friedhelm
Helling
U.S. Serial No. 08/475,784
Filed: June 7, 1995
Exhibit 1

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

